Near the end of the 20th century, the SlimFast diet became increasingly popular with weight-watchers, due in no small part to ...

mNational Institute for Health Research National Commercial Research Delivery Centre, Bradford, UK nNational Institute for Health Research Manchester Biomedical Research Centre, Manchester University ...

CVS Health will restore Eli Lilly's weight-loss injection Zepbound to its list of covered ‌drugs and add the drugmaker's ...

CVS Health will restore Eli Lilly’s weight-loss injection Zepbound to its list of covered drugs and also add the drugmaker’s ...

Eli Lilly continues strong execution, exceeding revenue expectations and expanding its pipeline with strategic, low-risk ...

CVS Health has announced a significant expansion of its coverage for Eli Lilly's weight-loss medications, confirming it will ...

Zepbound’s return as a preferred option reverses a prior formulary exclusion that maintained Wegovy coverage, underscoring how net pricing and rebate contracting drive PBM obesity access decisions.

Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming ...

Future stocks are some of Wall Street’s most exciting investments because they offer exposure to businesses expected to ...

From $65.3 million in 2025 to $200.6 million by 2029, driven by strong growth across all core segmentsGross profit growing ...